狄诺塞麦治疗骨转移疗效怎么样呢?
It is the first approved monoclonal antibody specifically targeting RANK ligand, also known as denosumab. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. Human RANKL mRNA is mainly found in bones, bone marrow and lymphoid tissues. Its main function in bones is to stimulate the differentiation and activity of osteoclasts and inhibit the apoptosis of osteoclasts.
How effective is denosumab in treating bone metastases?
The latest analysis of research presented at the European Society for Medical Oncology (ESMO) Annual Meeting in 2017 showed that among patients who could be surgically resected, 80% improved after receiving neoadjuvant denosumab: 44% underwent surgery with less impact on function, and 37% avoided surgery. In unresectable patients, denosumab resulted in effective long-term disease control, with a 5-year progression-free survival (PFS) rate of 88%.
In a phase III randomized, controlled clinical study led by Fizazi, the subjects were patients with prostate cancer bone metastases that were resistant to hormone therapy. Compared with zoledronic acid, denosumab also achieved encouraging results in terms of efficiency and safety in treating bone metastases. Denosumab showed advantages over zoledronic acid in delaying or preventing the first SHE.
To achieve the therapeutic effect of denosumab, correct medication method is also essential. Denosumab is administered as a subcutaneous injection of 120 mg into the upper arm, upper thigh, or abdomen, once every 4 weeks. It is used to treat bone metastases from solid tumors and prevent bone-related events in patients with bone metastases. When treatment or prevention of hypocalcemia is required, calcium and vitamin D are given.
The effect of treating bone metastases is very obvious, and it has been approved for marketing in China in May 2019, bringing good news to domestic patients. If you have other questions, you can also consult the medical companion passenger service.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)